In previous work, we presented ultevursen, an ASO designed to induce skipping of USH2A exon 13 for the treatment of USH2A-associated RP caused by pathogenic variants in exon 13,9 which is currently being evaluated in a phase 2b clinical trial (Trial #NCT06627179). This evidence concerns the gene USH2A and retinitis pigmentosa 1.